177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Authors
Keywords
-
Journal
Expert Review of Gastroenterology & Hepatology
Volume 13, Issue 11, Pages 1023-1031
Publisher
Informa UK Limited
Online
2019-10-26
DOI
10.1080/17474124.2019.1685381
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience
- (2019) Arvind Sahu et al. Journal of Oncology
- Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo
- (2019) Brian H. White et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms
- (2019) Eleftherios Chatzellis et al. NEUROENDOCRINOLOGY
- Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan
- (2019) Diane Reidy-Lagunes et al. CLINICAL CANCER RESEARCH
- Capecitabine and temozolomide in patients with advanced pulmonary carcinoid tumours
- (2019) George Papaxoinis et al. NEUROENDOCRINOLOGY
- Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms
- (2019) Taymeyah Al‐Toubah et al. ONCOLOGIST
- PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
- (2018) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
- (2018) Jingjing Zhang et al. JOURNAL OF NUCLEAR MEDICINE
- Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
- (2018) Martin H. Cherk et al. CANCER IMAGING
- Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms
- (2018) Richard P. Baum et al. Oncotarget
- First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.
- (2018) Melissa Lynne Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
- (2018) Jonathan R. Strosberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Acting Somatostatin Analog Therapy Differentially Alters68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions
- (2017) Narjess Ayati et al. JOURNAL OF NUCLEAR MEDICINE
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response
- (2017) Dwight H. Owen et al. Oncotarget
- Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
- (2017) Bryan Oronsky et al. NEOPLASIA
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- (2017) Arvind Dasari et al. JAMA Oncology
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC
- (2015) Stefano Severi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
- (2015) S. U. Dalm et al. JOURNAL OF NUCLEAR MEDICINE
- PRRT: Defining the Paradigm Shift to Achieve Standardization and Individualization
- (2014) L. Bodei et al. JOURNAL OF NUCLEAR MEDICINE
- Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
- (2014) D. Wild et al. JOURNAL OF NUCLEAR MEDICINE
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors
- (2014) Ebrahim S. Delpassand et al. PANCREAS
- Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience
- (2013) Robert L. Fine et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lutetium-labelled peptides for therapy of neuroendocrine tumours
- (2012) B. L. R. Kam et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
- (2011) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- (2011) Anna Imhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
- (2011) A. R. Haug et al. JOURNAL OF NUCLEAR MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
- (2010) Jonathan R. Strosberg et al. CANCER
- Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
- (2010) M. van Essen et al. JOURNAL OF NUCLEAR MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now